Actozone® Tablets

Pioglitazone 30, 45 mg

a) Use of Pioglitazone is associated with an increased risk of myocardial ischemic events such as angina or myocardial infarction.
b) Pioglitazone is not recommended (although not contraindicated) for use with patients who are taking insulin or nitrates

Composition
Each tablet contains
Active Ingredient:
Actozone® 30: Pioglitazone HCL 33 mg Eq. to 30 mg Pioglitazone base.
Actozone® 45: Pioglitazone HCL 49.5 mg Eq. to 45 mg Pioglitazone base.
Excipients:
Actozone® 30
Lactose Monohydrate, Hydroxypropyl Methylcellulose (Low viscosity), Microcrystalline Cellulose (Avicel PH 102), Sodium stearyl fumarate, Croscarmellose sodium, Quinoline yellow lake E104.
Actozone® 45
Lactose Monohydrate, Hydroxypropyl Methylcellulose (Low viscosity), Microcrystalline Cellulose (Avicel PH 102), Sodium stearyl fumarate , Croscarmellose sodium, Quinoline yellow lake E104
Carmine red colour E120
Clinical particulars
Therapeutic indications
Actozone® (Pioglitazone) is indicated as second or third line treatment of type 2 diabetes mellitus as described below:
as **monotherapy**
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
as **dual oral therapy** in combination with
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.
as **triple oral therapy** in combination with
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
- **Actozone**® (Pioglitazone) is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance .
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Posology and method of administration
Posology
Actozone® (Pioglitazone) treatment may be initiated at 15 mg or 30 mg once daily. The dose may be increased in increments up to 45 mg once daily.
In combination with insulin, the current insulin dose can be continued upon initiation of **Actozone**® (Pioglitazone) therapy. If patients report hypoglycaemia, the dose of insulin should be decreased.
Special population
Elderly
No dose adjustment is necessary for elderly patients. Physicians should start treatment with the lowest available dose and increase the dose gradually, particularly when pioglitazone is used in combination with insulin.
Renal impairment
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/min). No information is available from dialysed patients therefore pioglitazone should not be used in such patients.
Hepatic impairment
Pioglitazone should not be used in patients with hepatic impairment .
Paediatric population
The safety and efficacy of Pioglitazone in children and adolescents under 18 years of age have not been established. No data are available.
Method of administration
Pioglitazone tablets are taken orally once daily with or without food. Tablets should be swallowed with a glass of water.
Contraindications
Pioglitazone is contraindicated in patients with:
- hypersensitivity to the active substance or to any of the excipients .
- cardiac failure or history of cardiac failure (NYHA stages I to IV)
- hepatic impairment
- diabetic ketoacidosis
- current bladder cancer or a history of bladder cancer
- uninvestigated macroscopic haematuria
Special warnings and precautions for use
Recommendations For prescribers:
• Do not use pioglitazone in patients with active bladder cancer.
• Use pioglitazone with patients with a prior history of bladder cancer. The benefits of glycemic control versus unknown risks for cancer recurrence with pioglitazone should be considered in patients with a prior history of bladder cancer.
• Counsel patients to report any signs or symptoms of blood in urine, urinary urgency, Pain, on urination, or back or abdominal pain, as these may be due to bladder.
• Encourage patients to read the Medication Guide they get with their pioglitazone medicine.
• Report adverse events involving pioglitazone medicines.
Fluid retention and cardiac failure
Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually. Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin. Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Pioglitazone should be discontinued if any deterioration in cardiac status occurs.
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years. This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.
Elderly
Combination use with insulin should be considered with caution in the elderly because of increased risk of serious heart failure.
In light of age- related risks (especially bladder cancer, fractures and heart failure), the balance of benefits and risks should be considered carefully both before and during treatment in the elderly.
Bladder cancer
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11–6.31, P=0.029). After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.
Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). Any macroscopic haematuria should be investigated before starting pioglitazone therapy.
Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment.
Monitoring of liver function
There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8). It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. Liver enzymes should be checked prior to the initiation of therapy with pioglitazone in all patients. Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 X upper limit of normal) or with any other evidence of liver disease.
Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement. If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. If ALT levels remain > 3 X the upper limit of normal, therapy should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with pioglitazone should be guided by clinical judgement pending laboratory evaluations. If jaundice is observed, the medicinal product should be discontinued.
Weight gain
In clinical trials with pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. In some cases weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored. Part of the treatment of diabetes is dietary control. Patients should be advised to adhere strictly to a calorie-controlled diet.
Haematology
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. Similar changes were seen in metformin (haemoglobin 3–4% and haematocrit 3.6–4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1–2% and haematocrit 1–3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Hypoglycaemia
As a consequence of increased insulin sensitivity, patients receiving pioglitazone in dual or triple oral therapy with a sulphonylurea or in dual therapy with insulin may be at risk for dose-related hypoglycaemia, and a reduction in the dose of the sulphonylurea or insulin may be necessary.
Eye disorders
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Many of these patients reported concurrent peripheral oedema. It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
Others
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.5%) versus comparator (1.5%).
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).
Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women.
The risk of fractures should be considered in the long term care of patients treated with pioglitazone.
As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. These patients may be at risk of pregnancy. Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued .
Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). Glycaemic control should be monitored closely. Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered.
This Product contains Lactose Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose- galactose malabsorption should not take this medicine.
Interaction with other medicinal products and other forms of interaction
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4). Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be considered.
Fertility, pregnancy and lactation
Pregnancy
There are no adequate human data to determine the safety of pioglitazone during pregnancy. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth. The relevance of such a mechanism in humans is unclear and pioglitazone should not be used in pregnancy.
Breast-feeding
Pioglitazone has been shown to be present in the milk of lactating rats. It is not known whether pioglitazone is secreted in human milk. Therefore, pioglitazone should not be administered to breast-feeding women.
Effects on ability to drive and use machines
Actozone has no or negligible influence on the ability to drive and use machines. However patients who experience visual disturbance should be cautious when driving or using machines.
Undesirable effects
Tabulated list of adverse reactions
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (≥ 1/10); common (≥1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to< 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness.

Adverse reaction	**Frequency of adverse reactions of pioglitazone by treatment regimen**				
	Monotherapy	**Combination**			
		With metformin	**with sulpho-nylurea**	**With metformin and sulpho-nylurea**	**With insulin**
Infections and infestations					
upper respiratory tract infection	common	common	common	common	common
bronchitis					common
sinusitis	uncommon	uncommon	uncommon	uncommon	uncommon
Neoplasms benign, malignant and unspecified (including cysts and polyps)					
bladder cancer	uncommon	uncommon	uncommon	uncommon	uncommon
Blood and lymphatic system disorders					
anaemia		common			
Immune System Disorders					
hypersensitivity and allergic reactions [1]	not know	not know	not know	not know	not know
Metabolism and nutrition disorders					
hypo-glycaemia			uncommon	Very common	common
appetite increased			uncommon		
Nervous system disorders					
hypo-aesthesia	common	common	common	common	common
headache		common	uncommon		
dizziness			common		
insomnia	uncommon	uncommon	uncommon	uncommon	uncommon
Eye disorders					
visual disturbance [2]	common	common	uncommon		
macular oedema	not know	not know	not know	not know	not know
Ear and labyrinth disorders					
Vertigo			uncommon		
Cardiac disorders					
heart failure [3]					common
Respiratory, thoracic and mediastinal disorders					
dyspnoea					common
Gastrointestinal disorders					
flatulence		uncommon	common		
Skin and subcutaneous tissue disorders					
sweating			uncommon		
Musculoskeletal and connective tissue disorders					
fracture bone[4]	common	common	common	common	common
arthralgia		common		common	common
back pain					common
Renal and urinary disorders					
haematuria		common			
glycosuria			uncommon		
proteinuria			uncommon		
Reproductive system and breast disorders					
erectile dysfunction		common			
General disorders and administration site conditions					
Oedema[5]					Very common
fatigue			uncommon		
Investigations					
weight increased [6]	common	common	common	common	common
blood creatine phospho-kinase increased				common	
increased lactic dehydro-genase			uncommon		
alanine aminotransferase increased [7]	not know	not know	not know	not know	not know

Description of selected adverse reactions
[1] Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. These reactions include anaphylaxis, angioedema, and urticaria.
[2] Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.
[3] In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. In an outcome study of patients with pre-existing major

أكتـــوزون® أقراص

بيوجليتازون ٣٠، ٤٥ مجم

• إستخدام بيوجليتازون يرتبط مع زيادة خطر الأزمات القلبية مثل الذبحة الصدرية أو احتشاء عضلة القلب
• لا ينصح بأستخدام بيوجليتازون (وإن لم يكن من موانع الإستخدام) للمرضى الذين يأخذون الأنسولين أو النترات .

التركيب:

المواد الفعالة :

أكتوزون® ٣٠ مجم: يحتوى كل قرص أكتوزون على بيوجليتازون هيدروكلوريد ٣٣ مجم يكافئ ٣٠ مجم بيوجليتازون.

أكتوزون® ٤٥ مجم: يحتوى كل قرص أكتوزون على بيوجليتازون هيدروكلوريد ٤٩,٥ مجم يكافئ ٤٥ مجم بيوجليتازون.

المواد الغير فعالة:

أكتوزون® ٣٠ مجم: لاكتوز مونوهيدرات، هيدروكسي بروبيل ميثيل سيللبلوز، افيسيل PH102، صوديوم ستيريل فيومارات، كروس كارميللوز الصوديوم، لون اصفر كينولين.

أكتوزون® ٤٥ مجم: لاكتوز مونوهيدرات، هيدروكسي بروبيل ميثيل السيللبلوز، افيسيل PH102، صوديوم ستيريل فيومارات، كروس كارميللوز الصوديوم، لون اصفر كينولين، لون احمر كارمين.

ماهو أكتوزون® وما هى أستخداماته؟

يحتوى **أكتوزون®** على مادة بيوجليتازون مضاد السكرى و لعلاج النوع الثانى من مرض السكر (غير المعتمد على الأنسولين) وهو يحدث بعد سن البلوغ، عندما يكون ميتومرمن غير مناسب أو فشل ان يعمل بصورة كافية.

يساعد **أكتوزون®** على التحكم فى مستوى السكر فى الدم إذا كنت مصاب بالنوع الثانى من مرض السكر بمساعدة جسمك على تحسين كفاءة الأنسولين بالجسم. سوف يقوم طبيبك بفحصك لمعرفة إذا كان أكتوزون يعمل بكفاءة بعد ٢-٦ شهور من بداية العلاج به.

• يستعمل **أكتوزون®** بمفردة فى المرضى الغير قادرين على تناول ميتومرمن أو عندما يكون العلاج بالتمارين الرياضية وتنظيم الطعام فشل فى ضبط السكر بالدم ويمكن اضافتة إلى الأدوية الأخرى مثل ميتومرمن و/أو مجموعة سلفونيل يوريا والتى تستعمل لعلاج السكر عن طريق الفم أوالأنسولين حين تفشل هذة الأدوية فى السيطرة على السكر.

• ماذا يجب ان تعرف عن أكتوزون® قبل تناول أكتوزون®؟

-لا تتناول أكتوزون® إذا:

– كانت لديك حساسية لمادة بيوجليتازون أو أى مواد اخرى موجودة فى **أكتوزون®**.
• لديك هبوط بعضلة القلب أو كنت تعالج من هبوط عضلة القلب فى الماضى.
• لديك مشاكل بالكبد.
– لديك الحامض الكيتونى السكرى بالدم (من مضاعفات السكر يسبب فقدان الوزن بسرعة أو حدوث قيء منكر حاد).
– يجب الخاذ الأحتياطات الآتية مع **أكتوزون®** أقراص.
– هناك زيادة فى احتمالية الأصابة بسرطان المثانة عند استخدام مادة بيوجليتازون.
– لا يجب استخدام مادة بيوجليتازون إذا كنت تتناول علاج سرطان المثانه.
– أخبر طبيبك أذا ظهرت عليك أعراض سرطان المثانة الآتية:
• دم أو لون أحمر فى البول الحاجة الضرورية للتبول الم فى الظهر أو أسفل البطن.
• يجب قراءة النشرة المرفقة مع دواء بيوجليتازون.
• استشر طبيبك او الصيدلى إذا كان لديك أي استفسارات.
– يستخدم بيوجليتازون بحذر فى المرضى الذين سبق لهم الإصابة بسرطان المثانة.

• الاحتياطات والتحذيرات:

أخبر طبيبك أو الصيدلى قبل البدء فى العلاج بأكتوزون® إذا كان لديك:

– إحتياس فى البول أو هبوط بعضلة القلب وخصوصاً إذا كان السن أكبر من ٧٥ سنة. إذا كنت تأخذ مضاد الإلتهابات التى تسبب احتباس السوائل وتورم يجب ان تخبر طبيبك.
– إذا كانت لديك أمراض العين المصاحبة للسكر مثل تورم البقعة الصفراء (المنطقة المعتمة بالشبكية)
– تكيس بالمبايض أو كيس بالبيض هذا قد يؤدى إلى حدوث حمل نتيجة لعودة التبويض عند تناول **أكتوزون®**. لتجنب حدوث حمل إثناء تناول **أكتوزون®** يجب يتناول وسائل منع الحمل لتجنب حدوث حمل.
– مشاكل فى الكبد أو القلب. قبل البدء فى العلاج بإستعمال **أكتوزون®** يجب أن تقوم بعمل إختبار وظائف الكبد ويمكن تكراره على فترات محددة. بعض حالات مرضى السكر النوع الثانى لفترات طويلة أو مرضى القلب أو السكتة الدماغية الذين تم علاجهم باستخدام **أكتوزون®** والأنسولين،تم تسجيل حدوث هبوط بعضلة القلب. أخبر طبيبك إذا كان لديك أعراض هبوط بعضلة القلب مثل ضيق التنفس. زيادة الوزن نتيجة تورم الجسم والرجلين.

يجب إتخاذ الحذر عند تناول **أكتوزون®** مع أدوية السكر الأخرى من امكانية حدوث هبوط فى مستوى السكر بالدم.

• قد يحدث انيميا
• كسور العظام :
قد تحدث كسور بالعظام خصوصا مع السيدات مع بيوجليتازون وهذا سوف يتابعة طبيبك عند علاجك من السكر.
هذا المستخدم يحتوي علي الاكتوز إذا كان لديك حساسية من بعض السكريات أخبر طبيبك قبل تناول هذا الدواء .

الأطفال و المراهقين:

لايفضل استخدام بيوجليتازون فى الاطفال و المراهقين أقل من ١٨ سنة .

عند تناول أدوية أخرى مع أكتوزون®.

– أخبر طبيبك أو الصيدلى إذا كنت تتناول أو تناولت حديثا أو يجب ان تتناول أدوية اخرى .سواء بروشتة أو بدون روشتة .
– ولكن يمكن تناول الأدوية المعتادة مع **أكتوزون®** ولكن هناك بعض الأدوية قد تؤثر على مستوى السكر بالدم مثل:
• جيمفيبروزيل (لخفض الكوليسترول)
• ريفامبيسين (لعلاج الدرن الرئوى والأصابات البكتيرية الأخرى)
• أخبر طبيبك أو الصيدلى إذا كنت تأخذ أى منها فسوف يقوم بقياس السكر وقد يغير جرعة **أكتوزون®**

تناول أكتوزون® مع الطعام والمشروبات :

• يمكن تناول **أكتوزون®** مع أو بدون الطعام والشراب يجب تناول **أكتوزون®** بكوب كبير من الماء.

• الحمل والرضاعة الطبيعية :

أخبرى طبيبك إذا كنت:
– حاملاً أو تخططين لتصبحين حاملاً.
– تقومين بإرضاع طفلك رضاعة طبيعية فسوف ينصحك طبيبك بالتوقف عن تناول **أكتوزون®**

القياده و تشغيل الآلات:

لا يؤثر بيوجليتازون على القدرة على القيادة أو إستعمال الآلات ولكن يجب توخى الحذر عند حدوث رؤية غير طبيعية.

طريقة استعمال أكتوزون®:

تناول هذا الدواء كما أخبرك طبيبك أو الصيدلى .

– تكون الجرعة فى البداية هى من نصف إلى قرص واحد من **أكتوزون®** (١٥مجم – ٣٠ مجم) مرة واحدة فى اليوم . وعند الحاجة سوف يقوم طبيبك بزيادة الجرعة إلى ٤٥مجم فى اليوم .سوف يخبرك طبيبك عن الجرعة التى سوف تأخذها .
– إذا كان لديك إنطباع ان تأثير **أكتوزون®** ضعيف أخبر طبيبك بهذا .
– عند إستعمال **أكتوزون®** مع الأدوية الأخرى التى تستخدم لعلاج مرض السكر (مثل الأنسولين، كلوربرباميد، جليبنكلاميد، جليكلازيد، توليبوتاميد) سوف يخبرك طبيبك عن إذا كنت تحتاج الى جرعة اقل من هذة الأدوية .
– سوف يطلب منك طبيبك بعمل إختبار بأنتظام لمستوى السكر بالدم. مع ملاحظة ان كيدك سليم.
– إذا كنت تتناول طعام خاص بغرض السكر يجب الإستمرار عليه أثناء العلاج مع **أكتوزون®**.
– يجب أن تفحص وزنك بانتظام. فإذا زاد وزنك يجب أن تخبر طبيبك.

ماذا يحدث عند تناول جرعة زائدة من أكتوزون®:

• إذا حدث بطريق الخطأ وتناولت أو مريض آخر أو طفل كمية زائدة من **أكتوزون®** إذهب إلى الطبيب أو الصيدلى القريب لك فى الحال. حيث قد يحدث هبوط فى نسبة السكر بالدم عن الطبيعي وعليك بتناول سكريات. ينصح بعمل مكعبات السكر، حلويات، بسكويت أو عصير الفواكهة المحلى بالسكر.
• إذا نسيت تناول جرعة **أكتوزون®**
• تتناول **أكتوزون®** حسب الروشتة. لو نسيت جرعة، تناول فقط الجرعة التالية ولا تضاعف الجرعة.

إذا توقفت عن تناول أكتوزون®:

• يجب تناول **أكتوزون®** بانتظام يومياً. فإذا توقفت عن تناول **أكتوزون®** فسوف يرفع مستوى السكر بالدم أخبر طبيبك قبل التوقف عن تناول العلاج.

الأعراض الجانبية:

•مثل كل الأدوية، هذا الدواء قد يسبب بعض الأعراض الجانبية ولكن لا تحدث مع كل المرضى. بعض المرضى بصورة جزئية قد يحدث لهم هذة الاعراض الجانبية الخطيرة: فشل القلب، تم مشاهدته بصورة شائعة (يؤثر على ١ من كل ١٠ مرضى يأخذون بيوجليتازون مع أنسولين .
أعراض غير طبيعية مثل قصر التنفس أو زيادة الوزن بصورة سريعة أو تورم موضعى.
إذا حدث لك أى من هذة خصوصاً إذا كنت فوق سن ٦٥سنة، أسأل طبيبك فى الحال.
سرطان المثانة تم تسجيلة بصورة غير شائعة (قد يؤثر على ١من كل ١٠٠ مريض) فى المرضى الذين يأخذ بيوجليتازون . الأعراض والعلامات تشمل دم فى البول ،ألم عند التبول أوالرغبة الملحة للتبول إذا حدث لك أى من هذة أسأل طبيبك فى الحال . وارد جدا حدوث تورم موضعى (قد يؤثر على ١من كل ١٠ مرضى) فى المرضى الذين يأخذون بيوجليتازون مع الأنسولين. إذا حدث لك هذا العرض الجانبى أخبر طبيبك فى الحال. كسور بالعظام تم تسجيلها (يؤثر على ١من كل ١٠ مرضى) فى السيدات يتناولون بيوجليتازون وتم تسجيلها أيضا فى الرجال (لا يمكن حسابها) يتناولون بيوجليتازون إذا حدث لك هذا العرض الجانبى أخبر طبيبك. الرؤية غير واضحة نتيجة تورم (سوائل) خلف العين (لم يمكن حساب نسبتها من التقارير الواردة) تم تسجيلها فى المرضى الذين يأخذون بيوجليتازون.
إذا حدث لك هذا العرض الجانبى أخبر طبيبك فى الحال.
تفاعل الحساسية تم تسجيلها (لم يمكن حساب نسبتها فى التقارير الواردة) إذا حدث لك حساسية خطيرة، شاملاً مثل قرص النحل وتورم الوجه، الشفايف، اللسان، أو الحلق قد يسبب صعوبة فى التنفس أو البلع توقف عن تناول هذا الدواء فى الحال.
الأعراض الجانبية الأخرى التى تم تسجيلها مع بعض المرضى الذين يتناولون بيوجليتازون مثل:
أعراض جانبية شائعة: (من ١ لكل ١٠ مريض):
• عدوى الصدر. • رؤية غير طبيعية. • زيادة الوزن. • تتميل.
أعراض جانبية غير شائعة: (تؤثر على ١من كل ١٠٠ مريض):
• التهابات الجيوب الأنفية. • صعوبة فى النوم (أرق).
أعراض غير معروفة نسبتها:
• زيادة إنزيمات الكبد. • حساسية.
بعض الأعراض الجانبية الأخرى التى تم تسجيلها مع بيوجليتازون عند تناولة مع الأدوية الأخرى لعلاج السكر:
أعراض شائعة جداً (تؤثر على أكثر من ١ من كل ١٠ مريض):
• نقص مستوى السكر بالدم.
أعراض شائعة (تؤثر على ١-١٠ من كل ١٠٠ مريض):
•صداع. •دوخة. •ألم المفاصل. • ضعف جنسى. •ألم الظهر.
•صعوبة بالتنفس. • نقص كرات الدم الحمراء. • أنتفاخ.
اعراض جانبية غير شائعة (١من كل ١٠٠ مريض):
• سكر فى البول، زلال فى البول. • زيادة الأنزيمات. • دوار. • عرق.
• تعب. • زيادة الشهية.
– إذا حدث سوء لاى من الأعراض السابقة، أو لاحظت أي أعراض جانبية لم تكتب فى هذة النشرة يجب أن تخبر طبيبك أو الصيدلى.

ظروف التخزين:

يحفظ فى درجه حراره لا تزيد عن ٢٥ درجه مئوية وفى مكان جاف.

مدة الصلاحية:

٢ أعوام.

العبوة:

علبه كرتون تحتوي على ٢،١ (الومنيوم / شفاف عديم اللون بى فى سى / بى فى دى سى) شرائط يحتوي كل منها على ١٠ اقراص + نشره داخليه.

تحفظ جميع الأدوية بعيداً عن متناول الأطفال

AMOUN

إنتـــاج
شركة آمـــون للأدويـة ش.م.م
مدينة العبور، القليوبية، مصـر.

V08-21/11/2021
P150270.00
192

macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin. However, this did not lead to an increase in mortality in this study. In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged ≥ 65 years compared with those less than 65 years (9.7% compared to 4.0%). In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥ 65 years compared to 4.0% in patients less than 65 years. Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.

[4] A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration. A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). Post-marketing, bone fractures have been reported in both male and female patients .

[5] Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials. The oedema rates for comparator groups (sulphonylurea, metformin) were 2–5%. The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.

[6] In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2–3 kg over one year. This is similar to that seen in a sulphonylurea active comparator group. In combination trials pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. In comparator groups addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.

[7] In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. Mean levels of liver enzymes decreased with treatment with pioglitazone. Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. Although in very rare cases fatal outcome has been reported, causal relationship has not been established.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system (The Egyptian Pharmaceutical Vigilance Centre EPVC, email www.epvc .eg.com).

Overdose

In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.
Hypoglycaemia may occur in combination with sulphonylureas or insulin. Symptomatic and general supportive measures should be taken in case of overdose.

Pharmacological properties

Pharmacodynamic properties

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.
Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. A clinical trial of pioglitazone vs. glicazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of $HbA_{1c} \geq 8.0\%$ after the first six months of therapy). Kaplan–Meier analysis showed shorter time to treatment failure in patients treated with glicazide, compared with pioglitazone. At two years, glycaemic control (defined as $HbA_{1c} < 8.0\%$) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA_{1c} was similar between treatment groups after one year. The rate of deterioration of HbA_{1c} during the second year was less with pioglitazone than with gliclazide.
In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months. Patients receiving pioglitazone had a mean reduction in HbA_{1c} of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.
HOMA analysis shows that pioglitazone improves beta cell function as well as increasing insulin sensitivity. Two-year clinical studies have shown maintenance of this effect.
In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics. Pioglitazone was associated with significant weight gain. Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity. In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL cholesterol levels, compared with placebo, metformin or gliclazide. Pioglitazone did not cause statistically significant increases in LDL cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. These effects were independent of pioglitazone's effects on glycaemia and were statistically significantly different to glibenclamide.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. The study population had an average age of 62 years; the average duration of diabetes was 9.5 years. Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea. To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke. Approximately half of the study population had at least two of the cardiovascular history entry criteria. Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. However, the incidences of oedema, weight gain and heart failure were increased. No increase in mortality from heart failure was observed.

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with Pioglitazone in all subsets of the paediatric population in Type 2 Diabetes Mellitus.

Pharmacokinetic properties

Absorption

Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. Proportional increases of the plasma concentration were observed for doses from 2–60 mg. Steady state is achieved after 4–7 days of dosing. Repeated dosing does not result in accumulation of the compound or metabolites. Absorption is not influenced by food intake. Absolute bioavailability is greater than 80%.

Distribution

The estimated volume of distribution in humans is 0.25 l/kg.
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).

Biotransformation

Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups. This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. Three of the six identified metabolites are active (M-II, M-III, and M-IV). When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9, and 3A4 in man.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone.

Elimination

Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces. The mean plasma elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.

Elderly

Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.

Patients with renal impairment

In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. Thus free (unbound) pioglitazone concentration is unchanged.

Patients with hepatic impairment

Total plasma concentration of pioglitazone is unchanged, but with an increased volume of distribution. Intrinsic clearance is therefore reduced, coupled with a higher unbound fraction of pioglitazone.

Storage Condition:

Store at temperature not exceeding 25°C, In dry place

Shelf life:

3 years.

How supplied:

Carton Box containing 1, 2, 3 (AL / colorless transparent PVC/PVDC) Strips each of 10 tablets + insert leaflet.

Keep all medicaments out of reach of children

AMOUN

Product of:
AMOUN PHARMACEUTICAL CO. S.A.E.
El-Obour City, Al Qalyubia, Egypt.